ID: ALA2165608

Max Phase: Preclinical

Molecular Formula: C14H18N2O2

Molecular Weight: 246.31

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)(C)c1cccc(OCc2cc(=O)[nH][nH]2)c1

Standard InChI:  InChI=1S/C14H18N2O2/c1-14(2,3)10-5-4-6-12(7-10)18-9-11-8-13(17)16-15-11/h4-8H,9H2,1-3H3,(H2,15,16,17)

Standard InChI Key:  UVLPKOYPRVVZRK-UHFFFAOYSA-N

Associated Targets(Human)

Superoxide dismutase 173 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 246.31Molecular Weight (Monoisotopic): 246.1368AlogP: 2.58#Rotatable Bonds: 3
Polar Surface Area: 57.88Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.56CX Basic pKa: CX LogP: 2.23CX LogD: 2.02
Aromatic Rings: 2Heavy Atoms: 18QED Weighted: 0.87Np Likeness Score: -1.00

References

1. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,  55  (1): [PMID:22191331] [10.1021/jm2014277]

Source